NTRB Stock Forecast 2025-2026
Distance to NTRB Price Targets
NTRB Price Momentum
10 Quality Stocks Worth Considering Now
Researching Nutriband (NTRB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NTRB and similar high-potential opportunities.
Latest NTRB Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NTRB has a bullish consensus with a median price target of $13.00 (ranging from $13.00 to $13.00). Currently trading at $6.57, the median forecast implies a 97.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert LeBoyer at Noble Capital Markets, projecting a 97.9% upside. Conversely, the most conservative target is provided by Robert LeBoyer at Noble Capital Markets, suggesting a 97.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTRB Analyst Ratings
NTRB Price Target Range
Latest NTRB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTRB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 22, 2025 | Noble Capital Markets | Robert LeBoyer | Outperform | Initiates | $13.00 |
| Jul 26, 2022 | Small Cap Consumer Research | Eric Beder | Buy | Maintains | $21.00 |
Nutriband Inc. (NTRB) Competitors
The following stocks are similar to Nutriband based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nutriband Inc. (NTRB) Financial Data
Nutriband Inc. has a market capitalization of $73.41M with a P/E ratio of -9.4x. The company generates $2.02M in trailing twelve-month revenue with a 41.3% profit margin.
Revenue growth is +50.9% quarter-over-quarter, while maintaining an operating margin of -220.9% and return on equity of -80.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Nutriband Inc. (NTRB) Business Model
About Nutriband Inc.
Develops innovative transdermal drug delivery systems.
Nutriband Inc. generates revenue through the development and commercialization of transdermal products and technologies that enhance drug delivery. By focusing on improving safety and efficacy, the company aims to provide pharmaceutical and healthcare solutions that not only facilitate direct delivery to the bloodstream but also improve patient compliance and reduce side effects.
Nutriband's technologies have wide applications in the pharmaceutical and biotechnology industries, positioning the company as a key player in the transformation of drug delivery systems. Their innovative products could significantly impact various treatment areas and enhance patient experiences in healthcare settings.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Gareth Sheridan
Country
United States
IPO Year
2017
Website
www.nutriband.comNutriband Inc. (NTRB) Latest News & Analysis
Nutriband Inc. (NASDAQ: NTRB) received USPTO trademark registration for "Nutriband™" on February 18, 2025, enhancing its brand protection in the transdermal pharmaceutical market.
Nutriband's trademark registration enhances brand recognition and protection, potentially boosting its market position and attracting investors seeking growth in the pharmaceutical sector.
Nutriband and Kindeva have established an exclusive partnership to develop the Aversa™ Fentanyl patch, sharing development costs for milestone payments.
The partnership between Nutriband and Kindeva enhances growth potential through shared development costs, focusing on a unique product that addresses market needs in pain management and safety.
Nutriband Inc. (NASDAQ:NTRB) received a Notice of Allowance from the USPTO for its patent on Aversa™ abuse deterrent technology, enhancing its position in the transdermal pharmaceutical market.
Nutriband's patent allowance for its Aversa™ technology enhances its market position, potentially increasing revenue through exclusive rights and attracting investor interest in its growth prospects.
Nutriband Issues Letter to Shareholders
2 months agoNutriband Inc. (NASDAQ: NTRB) CEO Gareth Sheridan released a letter to shareholders detailing the company's 2024 achievements and 2025 outlook.
Nutriband’s CEO letter may signal company performance and strategic direction, impacting investor sentiment and stock valuation for 2025. Positive achievements can boost confidence and market activity.
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
3 months agoNutriband's abuse-deterrent technology is patented in 46 countries and plans to file for FDA approval for AVERSA™ Fentanyl in H1 2025.
Nutriband's patent coverage enhances its market position and potential revenue streams. FDA approval for AVERSA™ Fentanyl could significantly boost its valuation and investor interest.
Nutriband Inc. (NASDAQ:NTRB) announced its Q3 financial results for the period ending October 31, 2024, on December 4, 2024.
Nutriband's Q3 financial results can impact stock performance, investor sentiment, and future growth projections, influencing investment decisions in the company.
Frequently Asked Questions About NTRB Stock
What is Nutriband Inc.'s (NTRB) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Nutriband Inc. (NTRB) has a median price target of $13.00. The highest price target is $13.00 and the lowest is $13.00.
Is NTRB stock a good investment in 2025?
According to current analyst ratings, NTRB has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTRB stock?
Wall Street analysts predict NTRB stock could reach $13.00 in the next 12 months. This represents a 97.9% increase from the current price of $6.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nutriband Inc.'s business model?
Nutriband Inc. generates revenue through the development and commercialization of transdermal products and technologies that enhance drug delivery. By focusing on improving safety and efficacy, the company aims to provide pharmaceutical and healthcare solutions that not only facilitate direct delivery to the bloodstream but also improve patient compliance and reduce side effects.
What is the highest forecasted price for NTRB Nutriband Inc.?
The highest price target for NTRB is $13.00 from Robert LeBoyer at Noble Capital Markets, which represents a 97.9% increase from the current price of $6.57.
What is the lowest forecasted price for NTRB Nutriband Inc.?
The lowest price target for NTRB is $13.00 from Robert LeBoyer at Noble Capital Markets, which represents a 97.9% increase from the current price of $6.57.
What is the overall NTRB consensus from analysts for Nutriband Inc.?
The overall analyst consensus for NTRB is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are NTRB stock price projections?
Stock price projections, including those for Nutriband Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
